DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2023” report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the EGFR Non-Small Cell Lung Cancer Pipeline Report
- DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report depicts a robust space with 50+ EGFR Non-Small Cell Lung Cancer companies working to develop 50+ pipeline therapies for EGFR Non-Small Cell Lung Cancer treatment.
- The leading companies working in the EGFR Non-Small Cell Lung Cancer Market include Alpha Biopharma, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.
- Promising EGFR Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include AZD3759, AZD9291, BBT-207, Icotinib, naquotinib, midazolam, and others.
- December 2023: Cullinan Oncology Inc. announced a study of Phase 1 & 2 clinical trials for CLN-081. This is a Phase 1/2, open-label, multicenter, first-in-human trial to evaluate the safety and tolerability, PK, PD, and efficacy of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
- December 2023: Janssen Research & Development LLC announced a study of Phase 1 clinical trials for Amivantamab, Lazertinib, Carboplatin, and Pemetrexed. The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
Request a sample and discover the recent advances in EGFR Non-Small Cell Lung Cancer Treatment Drugs @ EGFR Non-Small Cell Lung Cancer Pipeline Outlook Report
In the EGFR Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
EGFR Non-Small Cell Lung Cancer Overview
Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers in non-small-cell lung cancer (NSCLC). Significant developments have taken place which highlight the differences in tumor biology that exist between the mutant and wild-type subtypes of NSCLC. Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain that regulates signaling pathways to control cellular proliferation.
Find out more about EGFR Non-Small Cell Lung Cancer Therapeutics Assessment @ EGFR Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products
EGFR Non-Small Cell Lung Cancer Emerging Drugs Profile
- AK112: Akeso Biopharma
- CLN-081: Cullinan Oncology
- BPI-361175: Betta Pharmaceuticals
- JANX008: Janux Therapeutics
EGFR Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key EGFR Non-Small Cell Lung Cancer companies which are developing the EGFR Non-Small Cell Lung Cancer therapies. The EGFR Non-Small Cell Lung Cancer companies which have their EGFR Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. phase III include, Akeso Biopharma.
DelveInsight’s EGFR Non-Small Cell Lung Cancer pipeline report covers around 42+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
EGFR Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Learn more about the emerging EGFR Non-Small Cell Lung Cancer Pipeline Therapies @ EGFR Non-Small Cell Lung Cancer Clinical Trials Assessment
Scope of the EGFR Non-Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- EGFR Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- EGFR Non-Small Cell Lung Cancer Companies- Alpha Biopharma, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Checkpoint Therapeutics, AbbVie, Akeso Biopharma, Cullinan Oncology, Betta Pharmaceuticals, EpimAb Biotherapeutics, Genor Biopharma, G1 Therapeutics, J Ints Bio, and others.
- EGFR Non-Small Cell Lung Cancer Pipeline Therapies- AZD3759, AZD9291, BBT-207, Icotinib, naquotinib, midazolam, and others.
Dive deep into rich insights for new drugs for EGFR Non-Small Cell Lung Cancer Treatment, Visit @ EGFR Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- EGFR Non-Small Cell Lung Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- EGFR Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- AK112: Akeso Biopharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CLN-081: Cullinan Oncology
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- JANX008: Janux Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- EGFR Non-Small Cell Lung Cancer Key Companies
- EGFR Non-Small Cell Lung Cancer Key Products
- EGFR Non-Small Cell Lung Cancer- Unmet Needs
- EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
- EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
- EGFR Non-Small Cell Lung Cancer Analyst Views
- EGFR Non-Small Cell Lung Cancer Key Companies
- Appendix
For further information on the EGFR Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to EGFR Non-Small Cell Lung Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market